A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study-Reference-Cited by-同舟云学术

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study

Published:2021-09-18 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Tang Xin,Li Yuan,Qian Wen-lei,Yan Wei-feng,Pang Tong,Gong You-ling,Yang Zhi-gang^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-021-03797-y.pdf

Reference34 articles.

1. Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C (2019) Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer 127:96–102. https://doi.org/10.1016/j.lungcan.2018.11.037

2. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22(20):5130–5140. https://doi.org/10.1158/1078-0432.Ccr-16-0399

3. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV (2016) Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies. J Thorac Oncol 11(11):2022–2026. https://doi.org/10.1016/j.jtho.2016.06.032

4. Chen Y, Wang S, Zhang B, Zhao Y, Zhang L, Hu M, Zhang W, Han B (2020) Clinical factors affecting the response to osimertinib in non-small cell lung cancer patients with an acquired epidermal growth factor receptor T790M mutation: a long-term survival analysis. Target Oncol 15(3):337–345. https://doi.org/10.1007/s11523-020-00724-y

5. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4(9):1046–1061. https://doi.org/10.1158/2159-8290.Cd-14-0337

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy of osimertinib in advanced non-small cell lung cancer with pleural metastasis: A four-year case study;Asian Journal of Surgery;2024-06

2. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21

3. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature;Medicine;2023-08-25